In recent weeks, researchers led by two BBRF grantees have reported encouraging results of a small pilot trial comparing the clinical and cognitive effects of electroconvulsive therapy (ECT) vs.…
Read More
Researchers led by a BBRF Scientific Council member report success in a preliminary test of a short-course, rapid-acting form of brain stimulation for treatment of people suffering from bipolar…
Read More
On May 28th, the U.S. Food and Drug Administration (FDA) approved cariprazine for the treatment of depressive episodes in adults with bipolar I disorder. Sold under the brand name Vraylar, the…
Read More
Cariprazine, a medicine approved by the FDA in 2015 for the treatment of manic episodes in bipolar I disorder, was effective in reducing depressive symptoms in bipolar I disorder patients in a phase…
Read More
Light therapy can be an effective treatment for seasonal depression, but there has been concern that the treatment might induce mania in people with bipolar disorder. Participants in the new trial…
Read More
